Research programme: Enoyl-ACP reductase inhibitors - Debiopharm Group/Nobelex Biotech
Alternative Names: FabI inhibitors - Debiopharm Group/Nobelex Biotech; Narrow-spectrum antibiotics - Debiopharm Group/ Nobelex BiotechLatest Information Update: 28 Jun 2023
Price :
$50 *
At a glance
- Originator Debiopharm Group; Nobelex Biotech
- Class Antibacterials; Small molecules
- Mechanism of Action Enoyl ACP reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gonorrhoea; Gram-negative infections; Helicobacter infections
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Gonorrhoea in Switzerland
- 28 Jun 2023 No recent reports of development identified for preclinical development in Helicobacter-infections in Switzerland
- 28 May 2021 No recent reports of development identified for research development in Gram-negative-infections in Switzerland